Nasdaq
$14.09▲ 0.11%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $6.29BShares out 4.500M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
17- 10.5After-hours26.10.06 06:008-KKey event#●●●#●●●#●●●
IOVANCE BIOTHERAPEUTICS, INC.Bullish
Iovance Biotherapeutics updated its corporate presentation on October 5, 2026, raising its full-year 2026 revenue guidance to $410 million–$420 million from the previous range of $350 million–$370 million. The company reported Q2 2026 revenue of approximately $304 million, exceeding guidance by over 10%, and stated that it has sufficient cash runway to fund operations into the second half of 2028.…more
$14.09+0.11%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.2After-hours26.10.03 06:014Ownership
IOVANCE BIOTHERAPEUTICS, INC.
Noah Berkowitz, an insider at Iovance Biotherapeutics, Inc. (IOVA), filed a Form 4 on October 2, 2026, reporting a change in beneficial ownership of securities as of September 30, 2026.…more
$14.09+0.11%vs prev closeView filingShare - 10.2After-hours26.10.03 06:003Ownership
IOVANCE BIOTHERAPEUTICS, INC.
Noah Berkowitz of Iovance Biotherapeutics (IOVA) has filed a Form 3, reporting his initial statement of beneficial ownership of securities. This filing serves as the official disclosure of his equity position in the company.…more
$14.09+0.11%vs prev closeView filingShare
16 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 1d agoRegular26.10.23 23:15#●●●#●●●
Iovance Reports Positive Phase 2 Data for TIL Therapy in Melanoma
Iovance announced positive Phase 2 results for its TIL therapy in frontline advanced melanoma, demonstrating high response rates and durable clinical benefits. These findings support the ongoing Phase 3 trial and potential future label expansion.…more
$14.09+0.11%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.16After-hours26.10.17 06:15
●●●●●●●● ●●●●● ●●●●●●
Iovance Biotherapeutics announced the grant of stock options covering 111,615 shares to 21 new non-executive employees. This award is part of the company's inducement plan to attract new talent under Nasdaq listing rules.…more
$14.09+0.11%vs prev close - 10.1Pre-market26.10.01 20:00
●●●●●●●● ●●●●● ●●●●●●
Iovance Biotherapeutics has appointed Dr. Noah Berkowitz, an expert in oncology drug development, as its new Chief Medical Officer. This leadership addition aims to accelerate the clinical development and expansion of the company's TIL therapy platform.…more
$14.09+0.11%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report